Dimensional Fund Advisors LP Increases Stock Position in REGENXBIO Inc. $RGNX

Key Points

• Dimensional Fund Advisors increased its REGENXBIO stake by 11.8% in the first quarter, bringing its holdings to 1.01 million shares worth approximately $8.5 million. Institutional investors and hedge funds collectively own 88.08% of the company.
• REGENXBIO beat second-quarter expectations with earnings of $0.43 per share and revenue of $108 million, while more than $200 million in new capital extended its cash runway into the fourth quarter of 2027.
• The company’s outlook depends on upcoming gene-therapy milestones, including RGX-202 and RGX-121 regulatory filings in 2026. Analysts remain divided, although the consensus rating is “Moderate Buy” with a $24 price target, and profitability and clinical execution risks remain significant.

Dimensional Fund Advisors LP grew its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 11.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,010,381 shares of the biotechnology company's stock after purchasing an additional 106,530 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.96% of REGENXBIO worth $8,464,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of REGENXBIO by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,374,140 shares of the biotechnology company's stock worth $48,588,000 after purchasing an additional 36,042 shares during the last quarter. State Street Corp boosted its stake in REGENXBIO by 15.2% in the 4th quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company's stock worth $32,929,000 after buying an additional 301,858 shares during the last quarter. AQR Capital Management LLC raised its stake in REGENXBIO by 5.6% during the fourth quarter. AQR Capital Management LLC now owns 1,361,962 shares of the biotechnology company's stock worth $19,612,000 after purchasing an additional 72,307 shares during the period. Integral Health Asset Management LLC increased its stake in REGENXBIO by 9.1% during the fourth quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the biotechnology company's stock worth $17,280,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of REGENXBIO by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 1,145,206 shares of the biotechnology company's stock worth $16,495,000 after purchasing an additional 19,658 shares during the period. 88.08% of the stock is currently owned by institutional investors and hedge funds.

Key REGENXBIO News

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Strong Q2 results: REGENXBIO reported earnings of $0.43 per share, well above analyst estimates of $0.08–$0.12, while revenue of $108.0 million exceeded the $97.6 million consensus estimate. The result compares with a $1.38-per-share loss in the year-ago quarter. REGENXBIO Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Key pipeline milestones remain on track: The company said its RGX-202 gene therapy filing for Duchenne muscular dystrophy is expected to begin in the third quarter of 2026, with potential accelerated approval in the second half of 2027. RGX-121 for Hunter syndrome is also targeted for resubmission in Q3 2026, while pivotal wet age-related macular degeneration data are expected in Q4 2026. REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Improved financial flexibility: More than $200 million of new capital raised in July increased pro forma cash, cash equivalents and marketable securities to over $310 million and extended the cash runway into the fourth quarter of 2027. This reduces near-term financing pressure as the company advances its programs. REGENXBIO Outlines Cash Runway
• Neutral Sentiment: Barclays maintained an Equal Weight rating and set a $12 price target, implying potential upside from recent trading levels but signaling a balanced view rather than a strong bullish recommendation. Barclays Rating Update
• Negative Sentiment: Profitability remains weak: Despite the quarterly beat, REGENXBIO continues to report a deeply negative net margin and return on equity, and analysts expect a full-year loss. Investors may therefore view the earnings improvement as less durable if it depends on licensing or other non-recurring revenue.
• Negative Sentiment: Material execution risk remains: The stock’s valuation and future upside depend heavily on successful regulatory filings, clinical data and eventual commercialization of its gene-therapy programs. Delays, safety concerns or disappointing trial results could pressure RGNX.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on RGNX shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of REGENXBIO in a report on Monday, June 8th. Zacks Research lowered shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 14th. HC Wainwright reiterated a "buy" rating and issued a $26.00 price target on shares of REGENXBIO in a report on Wednesday, July 1st. Morgan Stanley restated an "overweight" rating and set a $18.00 price objective on shares of REGENXBIO in a research note on Friday. Finally, Bank of America lowered their target price on REGENXBIO from $25.00 to $14.00 and set a "buy" rating for the company in a research note on Friday, May 15th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $24.00.

Insider Activity at REGENXBIO

In other news, insider Steve Pakola sold 36,725 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $12.86, for a total transaction of $472,283.50. Following the completion of the sale, the insider owned 213,009 shares of the company's stock, valued at approximately $2,739,295.74. This trade represents a 14.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 58,494 shares of company stock worth $718,232. Corporate insiders own 14.22% of the company's stock.

REGENXBIO Price Performance

NASDAQ:RGNX opened at $10.72 on Monday. The firm has a 50-day moving average of $10.02 and a two-hundred day moving average of $9.40. The stock has a market cap of $554.22 million, a P/E ratio of -2.83 and a beta of 0.94. REGENXBIO Inc. has a 1-year low of $5.45 and a 1-year high of $16.19.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.08 by $0.35. The business had revenue of $108.02 million for the quarter, compared to analysts' expectations of $97.63 million. REGENXBIO had a negative return on equity of 220.07% and a negative net margin of 112.58%. As a group, equities analysts expect that REGENXBIO Inc. will post -3.96 earnings per share for the current year.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO's pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source